Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis
Latest Information Update: 20 May 2024
At a glance
- Drugs Nintedanib (Primary)
- Indications COVID 2019 infections; Pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms NINTECOR
- 15 May 2024 Planned End Date changed from 1 May 2024 to 1 Jul 2024.
- 02 May 2022 Planned End Date changed from 1 Dec 2021 to 1 May 2024.
- 02 May 2022 Planned primary completion date changed from 1 Mar 2021 to 1 Oct 2023.